A5067660440- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Complement system in diseases
- Blood groups and transfusion
- Hemoglobinopathies and Related Disorders
- Telomeres, Telomerase, and Senescence
- Renal Diseases and Glomerulopathies
- Immunodeficiency and Autoimmune Disorders
- Renal Transplantation Outcomes and Treatments
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- Blood disorders and treatments
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- T-cell and B-cell Immunology
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cancer Genomics and Diagnostics
- Neutropenia and Cancer Infections
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Erythrocyte Function and Pathophysiology
- Adenosine and Purinergic Signaling
- Platelet Disorders and Treatments
- COVID-19 and healthcare impacts
- Iron Metabolism and Disorders
- CAR-T cell therapy research
King's College Hospital
2016-2025
King's College Hospital NHS Foundation Trust
2012-2025
King's College London
2009-2024
European Society for Blood and Marrow Transplantation
2024
Centre Hospitalier Universitaire de Toulouse
2024
German Red Cross
2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2024
Université de Lille
2024
NIHR Wellcome Trust Southampton Clinical Research Facility
2020-2024
Azienda Unità Sanitaria Locale Della Romagna
2023
BackgroundPersistent hemolytic anemia and a lack of oral treatments are challenges for patients with paroxysmal nocturnal hemoglobinuria who have received anti-C5 therapy or not complement inhibitors. Iptacopan, first-in-class factor B inhibitor, has been shown to improve hemoglobin levels in these patients.MethodsIn two phase 3 trials, we assessed iptacopan monotherapy over 24-week period less than 10 g per deciliter. In the first, anti-C5–treated were randomly assigned switch continue...
Summary Pancytopenia with hypocellular bone marrow is the hallmark of aplastic anaemia (AA) and diagnosis confirmed after careful evaluation, following exclusion alternate including hypoplastic myelodysplastic syndromes. Emerging use molecular cyto‐genomics helpful in delineating immune mediated AA from inherited failures (IBMF). Camitta criteria used to assess disease severity, which along age availability human leucocyte antigen compatible donor are determinants for therapeutic decisions....
ABSTRACT We retrospectively analyzed a large international cohort of 1113 patients with aplastic anemia to evaluate treatment choice and outcome in elderly as compared younger population. Overall, 319 (29%) were > 60 years old at diagnosis (60–64 ( n = 85), 106 65–69 106), 128 70 128)). Elderly showed more severe thrombocytopenia onset significantly lower overall response (complete plus partial) first‐line therapy 6 months (47% vs. 65%, p < 0.0001), irrespective modality (ATG or CyA...
Diagnostic criteria for hypoplastic myelodysplasic syndrome (h-MDS) have not been clearly established, making the differential diagnosis from other bone marrow failure syndromes (BMF) challenging. In this study, we aimed to delineate clinical, histopathological, and molecular features of h-MDS, based on a large well-annotated cohort patients with (BM) hypocellularity. The study included 534 consecutive adult hypocellular BM (278 h-MDS 136 aplastic anemia), 727 normo- or hypercellular MDS...
Abstract In this large single-centre study, we report high prevalence (25%) of, small (<10%) and very (<1%), paroxysmal nocturnal hemoglobinuria (PNH) clones by high-sensitive cytometry among 3085 patients tested. Given PNH association with bone marrow failures, analyzed 869 myelodysplastic syndromes (MDS) 531 aplastic anemia (AA) within the cohort. were more frequent larger in AA vs. MDS ( p = 0.04). clone, irrespective of size, was a good predictor response to immunosuppressive...
Emerging evidence suggests that activation of the complement system is critical in pathogenesis novel coronavirus, SARS-CoV-2, causative agent COVID-19-related lung injury. Inhibition terminal pathway by targeting protein 5 (C5) may be an effective therapeutic intervention CoV-mediated disease.1 Paroxysmal nocturnal haemoglobinuria (PNH) a rare, acquired haematopoietic stem cell (HSC) disease characterised intravascular haemolysis, increased thromboembolic risk and bone marrow failure.2 The...
Abstract Non-severe aplastic anemia is a rare bone marrow failure disorder characterized by variable degrees and combination of cytopenias, with limited data on management outcome. We describe large multicentric series 259 patients, focusing clinical molecular features, treatment, evolution, survival. The majority required treatment cyclosporine (CyA) alone ( N = 84) or in anti-thymocyte globulin (ATG,44) eltrombopag (20), (10), others (25) including androgens. Similar outcomes were observed...
Not available.
Abstract Background Benign ethnic neutropenia (BEN) is the most common cause of chronic seen in individuals African, Middle Eastern and West Indian descent. This phenotype broadly defined by an absolute neutrophil counts (ANC) below 1.8 × 10 9 cells/L absence other causes, without increased risk infection. BEN has been implicated as a potential source disparity patients treated with clozapine, antipsychotic choice treatment-resistant schizophrenia. Our main objective was to examine current...
Purpose To report a case of autosomal dominant dyskeratosis congenita (AD-DC) complicated by bilateral retinal vasculopathy and proliferative retinopathy with vitreous hemorrhage in the right eye, absence pancytopenia. Methods We 32-year-old woman who presented floaters her eye. She underwent complete ophthalmic examination fundus fluorescein angiography. Results Funduscopic revealed vascular sheathing temporal periphery both eyes Fluorescein angiography showed neovascularization eye...
Pre-emptive DLI (pDLI) is an effective strategy in lowering the risk of relapse without significantly increasing graft-versus-host disease (GVHD) case T cell lineage mixed chimerism (MC) post allogeneic transplant hematological malignancies. Many patients, however, fail to receive timely pDLI and have dismal outcomes, which are not taken into consideration. We compared long-term outcomes 106 patients having MC after day 60 undergoing stem allograft for acute leukemia from unrelated donor...
Survival after allogeneic hematopoietic cell transplantation (HSCT) for severe aplastic anemia (SAA) among older patients remains poor and associated with increased risk graft-versus-host disease (GVHD). In this retrospective study of 65 consecutive acquired SAA who were transplanted using fludarabine, low-dose cyclophosphamide, alemtuzumab (FCC), outcomes 27 aged at least 50 years compared those 38 younger than years. The median age the cohort was 61 (range, 51-71 years); 21 (78%) from...